Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 3-1 Month Momentum % is N/A% as of Aug. 26, 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,389 Biotechnology companies, ME Therapeutics Holding ranks better than 90.35% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-26), ME Therapeutics Holding's 3-1 Month Momentum % is N/A%.
The industry rank for ME Therapeutics Holding's 3-1 Month Momentum % or its related term are showing as below:
METXF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -9.31 * Ranked among companies with meaningful 3-1 Month Momentum % only.
ME Therapeutics Holding (OTCPK:METXF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ME Therapeutics Holding 3-1 Month Momentum % Related Terms
METXF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's 3-1 Month Momentum % falls into.
ME Therapeutics Holding (OTCPK:METXF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a 3-1 Month Momentum % of N/A% as of Aug. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #134 out of 1389 companies in the Biotechnology industry, placing it in the top 9.6%.
Is ME Therapeutics Holding's 3-1 Month Momentum % too high?
ME Therapeutics Holding's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, ME Therapeutics Holding ranks #134 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #134 out of 1389 companies for 3-1 Month Momentum %. This places ME Therapeutics Holding in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current 3-1 Month Momentum % is N/A% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
